

EVALUATION SUMMARY

Western Section AUA

Monday, October 27, - 10:00am - 12:00pm

PREP COURSE #3 - Kidney, Prostate, Bladder Cancer: Medical Oncology 101

	Scale: = POOR / ADEQUATE / EXCELLENT				
	1	2	3	4	5
PROGRAM OBJECTIVES	Total Pts	# Returned	Total Ave Score		
Determine the use of hormonal therapy and chemotherapy in advanced prostate cancer.	277	61	4.54		
Review the availability of targeted drugs and role of cytoreductive nephrectomy in advanced kidney cancer.	287	61	4.70		
Describe the use of chemotherapy in patients with muscle invasive bladder cancer.	272	61	4.46		

OVERALL EVALUATION

Increased Awareness of Subject	270	61	4.43
Will Influence How I Practice	259	61	4.25
Helped Me Improve Patient Care	259	61	4.25
Was Educationally Sound and Scientifically Balanced	276	61	4.52
Avoided Commercial Bias or Influence	283	61	4.64

Points that will influence the way I will practice:

Chemotherapy uses and indication with respect to new studies.

I will improve how I counsel patients and overall knowledge of these diseases.

Chemo for bladder cancer.

Early intervention helpful.

Neoadjuvant chemotherapy better than adjuvant chemotherapy for bladder cancer.

Will place more emphasis on bone density in patients undergoing ADT.

ADT for rising PSA.

Use of combined androgen blockade.

PRESENTERS

Sandy Srinivas, M.D.			
presenter demonstrated current knowledge of topic	277	61	4.54
Charles Ryan, M.D.			
presenter demonstrated current knowledge of topic	282	61	4.62
Lauren Harshman, M.D.			
presenter demonstrated current knowledge of topic	250	61	4.10

Comments about speakers/course content:

Excellent

Excellent presentation

Excellent review of chemotherapy by Dr. Srinivas.

I had difficulty reading slides. (I'll sit closer next time!)

Please amend slides.

More questions.

All informative!

Comments about speakers/course content: (CONTINUED)

Presentations comprehensive, but long.

Slides too small - hard to read.

Need more details on CAB risk & benefits.

Recommended topics for future meetings:

Case presentations & management.

Testis cancer.